Abstract:Study objective: To compare the effects of paroxetine on the pharmacokinetics and pharmacodynamics of the immediate-release (IR) and extended-release (ER) formulations of metoprolol. Design: Prospective, randomized, open-label, 3-way crossover study. Setting: General clinical research center. Subjects: Fifteen healthy volunteers with at least one active cytochrome P450 (CYP) CYP2D6 allele (CYP2D6*1 or CYP2D6*2). Intervention: In each of three phases conducted in random sequence, subjects received one of three metoprolol formulations administered on day 1: a single dose of metoprolol ER 100 mg, a single dose of metoprolol ER 200 mg, or two 100-mg doses of metoprolol IR administered 12 hours apart. Oral paroxetine 20 mg/day was then given alone on days 2-7 and coadministered with the same metoprolol formulation on day 8. Subjects received each of the other two formulations during the next two phases, with a 14-day washout period between each phase. Measurements and main results: After receiving metoprolol on days 1 (before paroxetine) and 8 (after paroxetine), S- and R-metoprolol pharmacokinetic parameters and exercise heart rate and blood pressure responses were measured. The mean area under the plasma concentration-time curve values of both S- and R-metoprolol for each formulation were increased approximately 3- and 4-fold, respectively, by paroxetine. Paroxetine significantly increased the S- and R-metoprolol maximum concentration (C(max)) of each formulation and increased the elimination half-life of both isomers approximately 2-fold. When metoprolol IR was given with paroxetine, the S-metoprolol C(max) was significantly greater than that of either the 100-mg or 200-mg ER products. The maximum effect of metoprolol IR on heart rate was significantly greater than that of metoprolol ER 200 mg, independent of whether the agents were administered alone or with paroxetine. Both the heart rate and systolic blood pressure area under the effect-time curve values were significantly decreased by paroxetine. Conclusion: Paroxetine significantly inhibits the metabolism of both metoprolol IR and ER, resulting in an increase in the magnitude and duration of [H9252]-blockade. The potential risk of adverse effects from excessive β-blockade may be greater with metoprolol IR than with metoprolol ER because of the significantly higher peak S-metoprolol plasma concentrations achieved with the IR formulation. Thus, if paroxetine treatment is indicated in patients receiving metoprolol, use of the ER formulation may reduce the risk of adverse effects.

Pharmacokinetics of immediate and sustained-release formulations of paroxetine: Population pharmacokinetic approach to guide paroxetine personalized therapy in chinese psychotic patients

Protocol for a Pharmacogenomic Study on Individualised Antipsychotic Drug Treatment for Patients with Schizophrenia.

Dose adjustment of paroxetine based on CYP2D6 activity score inferred metabolizer status in Chinese Han patients with depressive or anxiety disorders: a prospective study and cross-ethnic meta-analysis

Influence of CYP2D6 Genetic Polymorphism on Pharmacokinetics of Paroxetine in Chinese Healthy People

Analysis of prescriptions of three selective serotonin reuptake inhibitors from a perspective of metabolic interactions

Population pharmacokinetic approach to guide personalized sertraline treatment in Chinese patients

Modification of the association between paroxetine serum concentration and SERT-occupancy by ABCB1 (P-glycoprotein) polymorphisms in major depressive disorder

Optimizing the individual dosing of paroxetine in major depressive disorder with therapeutic drug monitoring

Escitalopram Personalized Dosing: A Population Pharmacokinetics Repository Method

Association Study of Multidrug Resistance 1 Gene Polymorphisms with Efficacy and Adverse Drug Reaction of Paroxetine in Major Depressive Patients

Escitalopram population pharmacokinetics and remedial strategies based on CYP2C19 phenotype

The impact of CYP3A5*3 on oral quetiapine: A population pharmacokinetic model in Chinese bipolar disorder patients

CYP2C19 Genotyping May Provide a Better Treatment Strategy when Administering Escitalopram in Chinese Population

Study on the pharmacokinetics of paroxetine hydrochloride tablets in healthy volunteers with HPLC-MS assay

[Population Pharmacokinetics Research of Clozapine in Chinese Schizophrenic Patients].

Pilot and Pivotal Study to Evaluate the Bioequivalence of Two Paroxetine 40 Mg Tablet Formulations in Healthy Chinese Subjects

Estimation of CYP2D6*10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay.

Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol

Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis

Population pharmacokinetic modeling of quetiapine after administration of SEROQUEL and SEROQUEL XR formulations to western and Chinese patients with schizophrenia, schizoaffective disorder or bipolar disorder.

Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism